Core Viewpoint - The article highlights the significant achievement of Yuanhua Intelligent Technology in obtaining the EU MDR certification for its orthopedic surgical robot, marking a crucial step for the company in entering the European and global markets [2][11]. Group 1: Certification and Regulatory Standards - The EU MDR regulations, implemented in 2021, are recognized as one of the highest regulatory standards in the global medical device field, with products lacking this certification unable to be sold in EU member states and other countries recognizing the CE mark [3]. - The certification process for high-risk medical devices like orthopedic surgical robots involves rigorous evaluation of the entire product lifecycle, including clinical evidence and post-market surveillance [4]. Group 2: Company Development and Product Innovation - Yuanhua Intelligent, established in 2018, has focused on the innovation and precision manufacturing of high-end specialized medical equipment, achieving significant breakthroughs in just seven years [5]. - The company has developed an integrated solution for orthopedic surgical robots, which includes "robot + software + consumables," and has created the world's first orthopedic surgical robot covering five major indications [6][8]. Group 3: Market Impact and Strategic Significance - The EU is the second-largest medical device market globally, valued at over €100 billion, and obtaining MDR certification allows Yuanhua Intelligent to apply for CE certification, facilitating access to European hospitals [11]. - The MDR certification is expected to have a spillover effect in emerging markets in Asia-Pacific, the Middle East, Africa, and Latin America, where EU standards often influence local regulatory policies [11]. Group 4: Competitive Positioning - The achievement of MDR certification positions Yuanhua Intelligent to compete with international giants in the high-end surgical robot market, showcasing China's capabilities in high-end medical equipment [13]. - The certification has led to the establishment of a closed-loop management system within the company, enhancing its organizational capabilities and laying the foundation for high-quality global development [13]. Group 5: Conclusion - The progress made by Yuanhua Intelligent in obtaining international certifications reflects the overall advancement of China's surgical robot industry, signaling the onset of a global era for Chinese surgical robots [14].

Core Viewpoint - The article discusses the emergence of "collaborative integrated surgical robots" as a new subclass of surgical robots, emphasizing their potential to enhance precision, safety, and efficiency in minimally invasive surgeries through multi-robot collaboration [1][2]. Group 1: Definition and Characteristics - The paper introduces the concept of "collaborative integrated surgical robots," defining them as a multi-robot system rather than a single tool extension, capable of executing complex multi-target tasks through collaboration [2]. - These robots can be homogeneous or heterogeneous, with different subsystems responsible for various surgical functions such as cutting, imaging, and drug delivery [2]. - The advantages of collaborative integrated surgical robots include high performance, multi-functionality, excellent interactive control, accurate positioning and visualization, and mixed drive capabilities [3][4][5]. Group 2: Key Technologies - The paper identifies four core technologies essential for the implementation of collaborative integrated surgical robots, which are crucial for achieving "precise minimally invasive" surgery [6]. - Multi-robot collaboration system integration, which forms the foundation of these surgical robots, has been successfully adopted in commercial products like the da Vinci surgical system [6][8]. - Various functional end-effectors that integrate with specialized surgical instruments enhance the operational capabilities of the robots [8]. - Sensor systems and intelligent control mechanisms are vital for closed-loop control and real-time tracking of surgical instruments within the patient [9]. - Medical imaging and navigation technologies are necessary for preoperative and intraoperative guidance, allowing for precise navigation to target areas [9]. Group 3: Collaborative Modes - The paper categorizes different collaborative modes of surgical robots based on surgical tasks, including: - Collaborative magnetic control surgical robots that use external magnetic fields to navigate micro-robots within the body for minimally invasive procedures [12]. - Collaborative rigid instrument surgical robots, exemplified by the da Vinci system, which are evolving towards higher autonomy [13][15]. - Collaborative soft instrument surgical robots made from flexible materials that can navigate complex anatomical structures [17]. - Collaborative multi-scale surgical robots that combine macro and micro robots for intricate tasks, addressing limitations of traditional surgery [18]. Group 4: Multidisciplinary Integration - The research highlights the interdisciplinary nature of collaborative integrated surgical robots, requiring inputs from clinical medicine, medical imaging, pathology, materials science, and control engineering to enhance their functionality and safety [21]. Group 5: Clinical Impact and Future Outlook - The paper presents clinical case studies demonstrating the advantages of these robots, such as reducing surgery time for rectal cancer from 227.5 minutes to 184 minutes and significantly lowering vascular injury rates in cardiovascular interventions [22]. - The introduction of collaborative integrated surgical robots represents a significant leap in surgical concepts, envisioning a future where surgical teams consist of various specialized robots working under the guidance of physicians [24].

Core Viewpoint - The successful completion of the first HX robotic arm-assisted total knee arthroplasty at the Fourth Medical Center of the Chinese People's Liberation Army signifies a significant advancement in the clinical application of domestic orthopedic surgical robots, moving from "technological breakthroughs" to "clinical popularization" [1][4]. Group 1: Surgical Procedure and Patient Background - The patient, a 61-year-old woman, had a 10-year history of osteoarthritis in both knees, with worsening pain and limited mobility in the right knee over the past two years, necessitating surgical intervention [3]. - Previous treatments, including sodium hyaluronate injections, failed to alleviate her symptoms, leading to the decision to use the HX robotic arm for the surgery due to the high precision and functional recovery requirements [3]. Group 2: Technology and Innovation - The HX robotic arm, developed by Yuanhua Intelligent Technology's subsidiary, is the only domestic company that has achieved full-chain independent research and development of core components for orthopedic surgical robots [4]. - The system utilizes preoperative CT data for 3D reconstruction, quantifying lower limb alignment and osteotomy range to create a personalized surgical plan [6]. - During the surgery, the optical tracking system provided real-time navigation with sub-millimeter accuracy, ensuring that the osteotomy thickness, prosthetic angle, and limb alignment met physiological requirements [6]. Group 3: Clinical Outcomes and Implications - The HX robotic arm maintained prosthetic position accuracy within sub-millimeter levels, significantly reducing postoperative pain, prosthetic loosening, and revision risks, while enabling smaller incisions and less trauma for faster patient recovery [6]. - Since its establishment in 2018, Yuanhua Intelligent has adhered to an independent technology route, breaking the international monopoly on high-end surgical robot core components and addressing the industry's long-standing reliance on imports [6]. - The successful implementation of the HX robotic arm at a top-tier hospital not only validates its safety and effectiveness in complex clinical scenarios but also demonstrates the adaptability and clinical value of domestic high-end medical equipment [6].

Summary of the Medical Robotics Industry Conference Call Industry Overview - The conference focused on the **medical robotics industry**, specifically discussing advancements in orthopedic surgical robots and related technologies. Key Points and Arguments Product Launch and Innovations - **Tianji 3.0** is set to launch in **June 2025**, featuring a self-developed seven-axis force feedback robotic arm, enabling AI-assisted automatic registration and intelligent surgical planning. It is expected to receive certification for unicondylar knee replacement by **2026** [2][4]. - The company has developed a **mobile CT** that reduces the terminal price from **4-6 million** to under **2 million**, enhancing surgical efficiency through deep integration with robotic systems [2][4]. - Revenue for **2025** is projected at **280 million** (up **60%** year-on-year), with a surgical volume of **49,000** cases. The guidance for **2026** is revenue of at least **350 million** and surgical volume of at least **60,000** cases [2][10]. Regulatory Changes and Market Impact - A new healthcare policy introduced in **January 2026** proposes a "price floor" and categorizes fees, expected to align nationwide by the end of **2026**, potentially leading to explosive growth in the industry by **2027** [2][8]. - The surgical volume is identified as a core metric for evaluating the company, serving as a basis for AI algorithm iteration and clinical acceptance [2][6]. AI Integration and Future Directions - The AI module in Tianji 3.0 is developed using external open-source models, focusing on proprietary data collection through clinical applications to enhance AI capabilities [5][12]. - Future plans include expanding AI functionalities to cover full-process support from diagnosis to post-operative care, with the potential for commercializing intelligent surgical planning [12][13]. Market Dynamics and Competitive Landscape - Traditional consumable companies are at a disadvantage in robotic development due to genetic mismatches and reliance on closed systems. Domestic robots are expected to accelerate the replacement of foreign brands due to cost-effectiveness and open systems [2][21]. - The integration of AI and robotics is anticipated to create new business models, particularly in remote surgery, which could significantly enhance market penetration in grassroots hospitals [14][15]. Financial Performance and Projections - The company achieved **280 million** in revenue in **2025**, a **60%** increase from **170 million** in **2024**, with **49,000** surgeries performed [10]. - For **2026**, the company aims for a minimum of **350 million** in revenue and **60,000** surgeries [10]. Challenges and Limitations - The adoption of surgical robots is hindered by inconsistent charging policies across provinces, with only **26** provinces allowing operating fees and **16** allowing consumable fees as of the end of **2025** [17]. - The psychological pressure on doctors to recommend robotic surgeries before clear guidelines are established may also limit usage [18]. Training and Collaboration - The company has established training centers in over **20** hospitals for in-service doctors and is exploring partnerships with universities to integrate robotic training into medical curricula [20]. Future Trends and Policy Implications - The introduction of unified pricing standards by the National Healthcare Security Administration is expected to enhance compliance and accelerate the adoption of surgical robots in hospitals [30]. - The focus on value-based pricing and the integration of AI in surgical procedures will likely drive innovation and improve patient outcomes [31][36]. Conclusion - The medical robotics industry is poised for significant growth driven by technological advancements, regulatory support, and evolving market dynamics. The integration of AI and the establishment of clear pricing and reimbursement policies will be crucial for the industry's future success.

Core Viewpoint - The orthopedic surgery robot market in China is poised for significant growth, with an expected annual increase of 8% in surgical volume, reaching over 3.52 million surgeries by 2025. However, the penetration rate of orthopedic surgical robots remains below 1%, far behind the anticipated 20% in the U.S. by 2026. This presents a substantial opportunity for domestic manufacturers to capitalize on the market gap [1]. Group 1: Market Dynamics - The aging population in China, with those aged 65 and above nearing 16%, is driving the demand for orthopedic surgeries [1]. - Currently, 23 provinces in China have included orthopedic robot-related costs in their fee schedules, with prices ranging from 8,000 to 40,000 yuan, indicating a decreasing self-pay ratio for patients [1]. - The orthopedic robot industry is expected to transition from a "technology validation period" to a "scale explosion period" due to improvements in payment policies, technological breakthroughs, and innovative business models [1]. Group 2: Technological Advancements - The core value of orthopedic robots lies in their ability to enhance surgical precision and address clinical challenges, significantly improving surgical efficiency and safety [4]. - Robots can reduce surgical time from 60-90 minutes to approximately 15 minutes, decrease X-ray exposure by about 70%, and lower the rate of screw misplacement in spinal surgeries from 15% to under 2% [5]. - The range of indications for robotic assistance is expanding, covering major surgical types such as spine, joint, and trauma surgeries, aligning well with the clinical needs of China's aging population [5]. Group 3: Domestic Market Trends - Domestic companies are increasingly replacing international giants in the orthopedic robot market, with significant advancements in core technologies [6]. - For instance, Yuanhua Intelligent's all-in-one orthopedic robot and Tianzhihang's robots have achieved international leading standards in precision and adaptability [6]. - Recent data indicates that domestic robots account for approximately 56% of sales volume and 36% of sales revenue in the past three years, driven by their compatibility with local procurement environments and cost advantages [9]. Group 4: Business Model Innovations - The success of international giants is attributed to their closed-loop ecosystem of "equipment + consumables + services," which has been less emphasized by early domestic companies [10]. - Recent shifts show that domestic firms like Tianzhihang and Aikang Medical are increasing their revenue from consumables and services, indicating a move towards a more sustainable business model [11]. Group 5: Future Outlook - The orthopedic surgical robot market in China is projected to grow at a CAGR of nearly 40% from 2025 to 2030, reaching a market size of 13.72 billion yuan, marking a golden development period for the industry [14]. - The competition will evolve from a focus on individual devices to a comprehensive ecosystem, necessitating domestic companies to break through technological barriers and establish a business model that meets both local and global market demands [14].

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $76.4 million, representing a 12% year-over-year growth [11] - U.S. revenue for the quarter was $66.6 million, reflecting a 10% growth compared to the prior year [11] - Gross margin for Q4 2025 was 60.6%, down from 64% in Q4 2024, primarily due to lower-than-expected U.S. consumable revenue and a one-time voluntary field action [13] - Net loss for Q4 2025 was $29.8 million, compared to a net loss of $18.9 million in Q4 2024 [14] - Adjusted EBITDA was a loss of $19 million in Q4 2025, compared to a loss of $10.3 million in the prior year [14] Business Line Data and Key Metrics Changes - Approximately 12,200 U.S. procedures were completed in Q4 2025, representing a 69% year-over-year growth [11] - Handpieces sold totaled 9,400 units at an average selling price of approximately $3,340, reflecting a 5% price increase compared to Q3 2025 [11] - Total U.S. handpiece and other consumable revenue was $34 million in Q4 2025, representing a 16% growth compared to Q4 2024 [12] - 65 new HYDROS systems were sold in Q4 2025, with an installed base of 718 systems, a 42% increase compared to year-end 2024 [12] Market Data and Key Metrics Changes - International revenue in Q4 2025 was $9.8 million, representing year-over-year growth of 25% [12] - The company expects 2026 total U.S. procedures to be in the range of 60,000-64,000, representing growth of approximately 39%-48% [15] Company Strategy and Development Direction - The company is focusing on increasing procedure volume, expanding margins, and achieving profitability while gaining market share [4] - A new integrated regional structure for the commercial team has been established to ensure better coordination around customer success and procedure growth [5] - A dedicated launch team has been formed to drive consistent launches and improve downstream utilization [5] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the financial performance in Q4 was lower than anticipated but emphasized that the changes made are critical for sustainable high growth and a clear path to profitability [19] - The company is confident in its long-term growth and profitability trajectory through 2026 and 2027 despite short-term disruptions [16] - Management expects to see benefits from the sales force realignment in the second half of the year [27] Other Important Information - The company has reset its 2026 guidance to $390 million-$410 million, representing annual growth of 27%-33% [9] - The average selling price for handpieces is expected to increase to $3,500 in 2026 [16] - The company plans to provide a detailed multi-year look at its financial guidance during the upcoming Investor Day [10] Q&A Session Summary Question: What unfolded in Q4 regarding handpiece sales? - Management indicated that the softness in handpiece sales was influenced by customer purchasing behavior and the elimination of bulk purchase discounts [21][22] Question: Why is there confidence in back-end loaded growth for 2026? - Management explained that the sales force's maturity and the new alignment would take time but are expected to yield benefits in the latter half of the year [27] Question: What gives confidence in a 1-to-1 ratio of handpiece sales to procedures in 2026? - Management noted that historical data showed handpiece sales were typically higher than procedure volumes, but recent changes are expected to align them more closely [31][32] Question: Are there concerns about customer dissatisfaction due to the end of bulk purchase deals? - Management does not anticipate dissatisfaction and believes that ordering patterns will stabilize without bulk discounts [39] Question: What is the health of underlying demand for procedures? - Management reported strong procedure growth of nearly 70% year-over-year, indicating healthy demand despite revenue shortfalls due to customer ordering behavior [52][53]

Core Viewpoint - The article discusses the development of an artificial kinaesthesia framework by a research team at The Chinese University of Hong Kong, aimed at overcoming the limitations of current surgical robots that heavily rely on visual data, thereby enhancing their tactile perception and adaptability in complex surgical environments [4][12]. Group 1: Artificial Kinaesthesia Framework - The proposed framework consists of three layers: physical perception, algorithm interpretation, and collaborative control, enabling robots to not only "see" but also "feel" and "understand" the physical interactions during surgery [5][11]. - The physical perception layer focuses on equipping surgical instruments with sensory capabilities, integrating proprioception and exteroception to replicate human-like tactile feedback [8][9]. - The algorithm interpretation layer aims to provide semantic meaning to the sensory data, allowing robots to process feedback in a two-tiered manner similar to human surgeons, distinguishing between reflexive adjustments and cognitive decision-making [10]. Group 2: Challenges and Solutions - The collaborative control layer seeks to create a closed-loop system that integrates physical perception and algorithm interpretation, enabling robots to execute tasks with greater flexibility and precision [11]. - The article emphasizes the need for a multi-modal model that combines visual, tactile, and linguistic information to enhance the robot's situational awareness and operational adaptability [11]. Group 3: Future Implications - The introduction of the artificial kinaesthesia framework signifies a shift from vision-dependent surgical robots to intelligent partners capable of multi-sensory collaboration, ultimately leading to safer and more precise minimally invasive treatments for patients [12][13].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公司董事會（「董事會」）欣然宣佈，截至本公告日，本集團核心產品圖邁®腔 鏡手術機器人（「圖邁」）全球商業化訂單突破200台，覆蓋近50個國家和地區， 已完成商業化裝機近130台。圖邁商業化訂單和裝機規模的再次里程碑式躍升， 標誌著其臨床價值在全球範圍內獲得持續、廣泛的認可，是對圖邁安全性、穩 定性、可靠性的系統性認證。來自不同國家、不同醫療體系、不同專科背景的 外科醫生，正在以真實而審慎的臨床決策，將圖邁納入日常手術實踐與長期學 科建設之中。 在已覆蓋的近50個國家和地區中，訂單數超5台的達12個，新興市場代表印度、 巴西、阿根廷增長強勁，其中印度累計訂單已達14台，巴西超過10台；發達國 家市場持續突破，西班牙、澳大利亞等國家成為快速增長點。圖邁商業化已在 全球範圍內形成多區域協同共振的新格局，貫穿發展中國家新興市場以及發 達國家成熟醫療體系。 （於中華人民共和國註冊成立的股份有限公司） – 1 – ...

Core Viewpoint - The article emphasizes the significance of the HX self-developed orthopedic surgical robot, marking a milestone in China's surgical robot industry, which has been in development for over a decade [1][3]. Group 1: Technological Advancements - The HX system represents a shift from relying on foreign components to a fully self-developed surgical robot, showcasing a six-axis robotic arm capable of precise movements in a surgical environment [3][5]. - The design of the HX robotic arm incorporates a hybrid structure of serial and parallel configurations, ensuring a wide working space while maintaining high rigidity and agility, essential for orthopedic surgeries [8][10]. - Each joint of the robotic arm is independently driven, enhancing control capabilities and allowing for complex movements, which is crucial for executing intricate surgical tasks [10]. Group 2: Safety Mechanisms - The HX system implements a three-tier safety protection system, which includes real-time resistance sensing to prevent accidental cuts to vital tissues [12][13]. - Hard safety limits are established for bone cutting edges, depth, and angles, ensuring that the robot operates within predefined safe parameters [14]. - The system features real-time dynamic compensation to adjust for patient movements during surgery, maintaining tool alignment with the intended path [14][16]. Group 3: Data and Research Integration - The HX system is designed as an open and expandable platform, enabling data collection from each surgery to support research and clinical innovation in orthopedic procedures [19]. - Collaborations with top medical institutions across China aim to integrate industry, academia, and clinical practice, fostering a feedback loop for continuous technological improvement [19]. Group 4: Future Implications - The successful operation of the HX robotic arm at West China Hospital symbolizes a significant step towards the autonomy of high-end medical equipment in China, reducing reliance on foreign technology [21]. - The potential for the HX system to be utilized in more grassroots hospitals signifies a broader accessibility to advanced surgical techniques, promoting the concept of precision medicine in orthopedics [21][22].

Investment Rating - The report maintains a "Buy" rating for the company [6][8]. Core Insights - The company is a leading player in the orthopedic surgical robot industry in China, focusing on reshaping surgical processes through intelligent technology and integrating upstream and downstream resources [3][16]. - The company has launched multiple generations of orthopedic surgical robots, with significant advancements in product capabilities and regulatory approvals, including the first all-in-one orthopedic surgical robot [3][5]. - The policy environment is becoming increasingly favorable for surgical robots, with expectations of broader inclusion in medical insurance coverage, which could significantly boost the company's market potential [4][48]. - The consumables and services segment is projected to become a major growth driver, with increasing surgical volumes and a growing demand for related services [5][28]. - Financial forecasts indicate strong revenue growth, with expected revenues of 275 million, 396 million, and 567 million yuan for 2025, 2026, and 2027 respectively, alongside a path to profitability by 2027 [6][9]. Company Overview - The latest closing price is 22.79 yuan, with a total market capitalization of 10.4 billion yuan [2]. - The company has a total share capital of 456 million shares, with a debt-to-asset ratio of 24.3% [2]. - The company has a unique business model that combines equipment sales, consumables, and technical services, aiming for a comprehensive service approach [24]. Market Dynamics - The global orthopedic surgical robot market is expected to grow significantly, driven by an aging population and the increasing demand for precise surgical interventions [31][36]. - The domestic market is characterized by a "one strong, many strong" competitive landscape, with the company holding over 40% market share in China [41][43]. - The report highlights the potential for rapid growth in the orthopedic surgical robot market, with projections indicating a compound annual growth rate of 33.3% from 2026 to 2030 [36][47]. Financial Performance - The company has maintained a high gross margin, with a sales gross margin of 70.2% in 2024, expected to improve further in subsequent years [30]. - Revenue for the first three quarters of 2025 reached 187 million yuan, reflecting a year-on-year growth of 103.5% [29][32]. - The company is on track to reduce losses, with forecasts indicating a return to profitability by 2027 [6][9].